NASHVILLE, TN – Pathfinder Therapeutics, Inc. (PTI), a medical device company focused on the development of “surgical GPS†systems for the abdomen, announced that it has closed on a $5.2 million Series A financing round led by Hatteras Venture Partners of Research Triangle Park, NC. Other investors included
Florida Gulfshore Capital, Clayton & Associates, Nashville Capital Network, Lumira, and Vanderbilt University. (more…)
RESEARCH TRIANGLE PARK, N.C.- Arthur M. Pappas, MBA, founder and managing partner of the Research Triangle Park venture capital firm Pappas Ventures, has been elected chairman of the North Carolina Biotechnology Center’s Board of Directors. (more…)
WASHINGTON, DC — The Biotechnology Industry Organization (BIO) presented Florida Senate President Ken Pruitt (R-Port St. Lucie) with a Legislator of the Year Award for 2007-2008. (more…)
RESEARCH TRIANGLE PARK, NC– CeNeRx BioPharma, Inc., a clinical
stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $15 million Series B financing. Existing investors Aisling Capital, L Capital Partners and Pappas Ventures participated in the funding round. CeNeRx plans to use the proceeds to conduct a Phase II clinical trial of its lead product
candidate Tyrimaâ„¢ for the treatment of major depressive disorder (MDD), to further characterize its novel preclinical cannabinoid pipeline and potentially to acquire additional development stage
compounds targeted at CNS disorders. (more…)
Atlanta, GA – Southeast BIO (SEBIO) today announced the keynote speakers and featured panelists for the Tenth Anniversary Southeastern BIO Investor Forum. The Forum, scheduled for December 4-5, 2008 at the Breakers Resort in Palm Beach, FL, will feature remarks from more than a dozen industry leaders. (more…)
ATLANTA, GA — On October9,2008, Shionogi & Co. FloxinFLOXIN® Otic website, a source for information about Otitis Media (middle eRead about ofloxacin (Floxin) an antibiotic prescribed to treat pneumonia,FloxinPhysician reviewed FloxinRead the Medication Guide that comes with FLOXINDistinct from other ototopical medications, FLOXINWhat is the most important information I should know about FloxinFLOXINBrand Name(s): FloxinThis leaflet contains important information about FLOXINPharmLand offers the biggest selection of generic drugs including, Floxin. Get amazing prices on FloxinGet the Answers You’re Looking For. Floxin “Daiichi is pleased to offer patients and physicians a once-daily dosing regimen of Floxin Otic, a proven sRead the Medication Guide that comes with FLOXIN before you start taking it and What is the most important information I should know about FLOXIN. FLOXIN® Otic website, a source for information about Otitis Media (middleLearn about FloxinFind medical information for Floxinthat irreversible peripheral neuropathy was associated with Floxin. , Ltd. (”Shionogi”) and Sciele Pharma, Inc. (”Sciele”) (NASDAQ: SCRX) announced the completion of Shionogi’s acquisition of Sciele for US$3 Store ratings. Fantastic prices and quality of all pills. Inderal Includes patient rankings on scale of 1-5, comments, side effects, sex, age, time taken. Learn about the prescription medication Inderal (Propranolol), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. 1.00 per share in cash. Shionogi completed the acquisition through a cash tender offer followed by short-form merger of the indirect wholly owned subsidiary of Shionogi with and into Sciele. Sciele is now an indirect wholly owned subsidiary of Shionogi. (more…)
DURHAM, NC - Aldagen Inc., which is developing clinical stage regeneration therapies, has withdrawn its registration for an $80.5 million initial offering of public stock. (more…)
PITTSBORO, NORTH CAROLINA- Biolex Therapeutics, Inc. announced the closing of a $60 million Series D financing led by Clarus Ventures, a leading biotechnology investor, with OrbiMed Advisors participating as a new investor. Existing investors participating in the financing included Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corporation, Investor Growth Capital, Polaris Ventures, Mitsui & Company, The Dow Chemical Company, JP Morgan Securities and the North
Carolina Economic Development Fund. (more…)
PORT ST. LUCIE, FL — In Florida’s biotech building race, the Torrey Pines Institute for Molecular Studies has finished first.
Building Official Joel Dramis declared construction of Torrey Pines’ new $40 million facility complete during a brief ceremony Tuesday in the front lobby of the new building. Suffolk Construction Co. finished the 100,000-square-foot facility more than three months ahead of the scheduled completion date of January 2009. (more…)
